Advertisement
Screener

CYTOKINETICS, INCORPORATED (CYTK) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

2.8 / 5 stars · 68/120 Roast Me

CYTOKINETICS, INCORPORATED Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

CYTOKINETICS, INCORPORATED (CYTK) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$404.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Income Statement › Net Income

us-gaap:ProfitLoss · last filed 2026-08-06

  • CYTOKINETICS, INCORPORATED net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$198.76M.
  • CYTOKINETICS, INCORPORATED net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$206.03M.
  • CYTOKINETICS, INCORPORATED net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$183.03M.
  • CYTOKINETICS, INCORPORATED net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$306.18M.
  • CYTOKINETICS, INCORPORATED net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$784.96M.
  • CYTOKINETICS, INCORPORATED net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$589.53M.
  • CYTOKINETICS, INCORPORATED net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$526.24M.
  • CYTOKINETICS, INCORPORATED net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$388.95M.
Period endNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 167 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 170 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 173 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 176 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 179 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 182 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 185 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 188 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 191 month
2026-06-30-$198.76M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$404.79M
10-Q · filed 2026-08-06
-$587.82M
derived: sum of 3 quarters · filed 2026-08-06
-$894.00M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$206.03M
10-Q · filed 2026-05-05
-$389.06M
derived: sum of 2 quarters · filed 2026-05-05
-$695.24M
derived: sum of 3 quarters · filed 2026-05-05
-$829.61M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$183.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$489.21M
derived: sum of 2 quarters · filed 2026-02-26
-$623.58M
derived: sum of 3 quarters · filed 2026-08-06
-$784.96M
10-K · filed 2026-02-26
2025-09-30-$306.18M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
-$440.55M
derived: sum of 2 quarters · filed 2026-08-06
-$601.92M
10-Q · filed 2025-11-05
-$751.94M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$134.37M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$295.75M
10-Q · filed 2026-08-06
-$445.77M
derived: sum of 3 quarters · filed 2026-08-06
-$606.31M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$161.38M
10-Q · filed 2026-05-05
-$311.40M
derived: sum of 2 quarters · filed 2026-05-05
-$471.94M
derived: sum of 3 quarters · filed 2026-05-05
-$615.26M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31-$150.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$310.56M
derived: sum of 2 quarters · filed 2026-02-26
-$453.88M
derived: sum of 3 quarters · filed 2026-02-26
-$589.53M
10-K · filed 2026-02-26
2024-09-30-$160.54M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
-$303.86M
derived: sum of 2 quarters · filed 2025-11-05
-$439.51M
10-Q · filed 2025-11-05
-$576.40M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30-$143.32M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$278.96M
10-Q · filed 2025-08-07
-$415.86M
derived: sum of 3 quarters · filed 2026-02-26
-$545.28M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31-$135.64M
10-Q · filed 2025-05-06
-$272.54M
derived: sum of 2 quarters · filed 2026-02-26
-$401.96M
derived: sum of 3 quarters · filed 2026-02-26
-$530.60M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31-$136.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$266.32M
derived: sum of 2 quarters · filed 2026-02-26
-$394.95M
derived: sum of 3 quarters · filed 2026-02-26
-$526.24M
10-K · filed 2026-02-26
2023-09-30-$129.42M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
-$258.06M
derived: sum of 2 quarters · filed 2024-11-07
-$389.35M
10-Q · filed 2024-11-07
-$526.73M
derived: sum of 4 quarters · filed 2025-02-27
2023-06-30-$128.64M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09
-$259.93M
10-Q · filed 2024-08-09
-$397.31M
derived: sum of 3 quarters · filed 2025-02-27
-$539.62M
derived: sum of 4 quarters · filed 2025-02-27
2023-03-31-$131.29M
10-Q · filed 2024-05-10
-$268.67M
derived: sum of 2 quarters · filed 2025-02-27
-$410.98M
derived: sum of 3 quarters · filed 2025-02-27
-$430.80M
derived: sum of 4 quarters · filed 2025-02-27
2022-12-31-$137.38M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
-$279.69M
derived: sum of 2 quarters · filed 2025-02-27
-$299.51M
derived: sum of 3 quarters · filed 2025-02-27
-$388.95M
10-K · filed 2025-02-27
2022-09-30-$142.31M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03
-$162.13M
derived: sum of 2 quarters · filed 2023-11-03
-$251.57M
10-Q · filed 2023-11-03
-$282.14M
derived: sum of 4 quarters · filed 2024-02-28
2022-06-30-$19.82M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03
-$109.27M
10-Q · filed 2023-08-03
-$139.84M
derived: sum of 3 quarters · filed 2024-02-28
-$215.92M
derived: sum of 4 quarters · filed 2024-02-28
2022-03-31-$89.44M
10-Q · filed 2023-05-05
-$120.02M
derived: sum of 2 quarters · filed 2024-02-28
-$196.10M
derived: sum of 3 quarters · filed 2024-02-28
-$257.65M
derived: sum of 4 quarters · filed 2024-02-28
2021-12-31-$30.57M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28
-$106.66M
derived: sum of 2 quarters · filed 2024-02-28
-$168.21M
derived: sum of 3 quarters · filed 2024-02-28
-$215.31M
10-K · filed 2024-02-28
2021-09-30-$76.09M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04
-$137.64M
derived: sum of 2 quarters · filed 2022-11-04
-$184.74M
10-Q · filed 2022-11-04
-$228.67M
derived: sum of 4 quarters · filed 2023-03-01
2021-06-30-$61.55M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05
-$108.66M
10-Q · filed 2022-08-05
-$152.59M
derived: sum of 3 quarters · filed 2023-03-01
-$155.76M
derived: sum of 4 quarters · filed 2023-03-01
2021-03-31-$47.10M
10-Q · filed 2022-05-06
-$91.03M
derived: sum of 2 quarters · filed 2023-03-01
-$94.21M
derived: sum of 3 quarters · filed 2023-03-01
-$134.99M
derived: sum of 4 quarters · filed 2023-03-01
2020-12-31-$43.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
-$47.10M
derived: sum of 2 quarters · filed 2023-03-01
-$87.89M
derived: sum of 3 quarters · filed 2023-03-01
-$127.29M
10-K · filed 2023-03-01
2020-09-30-$3.17M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05
-$43.95M
derived: sum of 2 quarters · filed 2021-11-05
-$83.36M
10-Q · filed 2021-11-05
-$114.00M
derived: sum of 4 quarters · filed 2022-02-25
2020-06-30-$40.78M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06
-$80.19M
10-Q · filed 2021-08-06
-$110.83M
derived: sum of 3 quarters · filed 2022-02-25
-$140.40M
derived: sum of 4 quarters · filed 2022-02-25
2020-03-31-$39.41M
10-Q · filed 2021-05-07
-$70.05M
derived: sum of 2 quarters · filed 2022-02-25
-$99.62M
derived: sum of 3 quarters · filed 2022-02-25
-$131.73M
derived: sum of 4 quarters · filed 2022-02-25
2019-12-31-$30.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25
-$60.21M
derived: sum of 2 quarters · filed 2022-02-25
-$92.33M
derived: sum of 3 quarters · filed 2022-02-25
-$121.69M
10-K · filed 2022-02-25
2019-09-30-$29.57M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06
-$61.69M
derived: sum of 2 quarters · filed 2020-11-06
-$91.05M
10-Q · filed 2020-11-06
-$117.52M
derived: sum of 4 quarters · filed 2021-02-26
2019-06-30-$32.11M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
-$61.48M
10-Q · filed 2020-08-07
-$87.95M
derived: sum of 3 quarters · filed 2021-02-26
-$109.96M
derived: sum of 4 quarters · filed 2021-02-26
2019-03-31-$29.37M
10-Q · filed 2020-05-08
-$55.83M
derived: sum of 2 quarters · filed 2021-02-26
-$77.85M
derived: sum of 3 quarters · filed 2021-02-26
-$105.37M
derived: sum of 4 quarters · filed 2021-02-26
2018-12-31-$26.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26
-$48.48M
derived: sum of 2 quarters · filed 2021-02-26
-$76.01M
derived: sum of 3 quarters · filed 2021-02-26
-$106.29M
10-K · filed 2021-02-26
2018-09-30-$22.02M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-01
-$49.54M
derived: sum of 2 quarters · filed 2019-11-01
-$79.82M
10-Q · filed 2019-11-01
-$120.31M
derived: sum of 4 quarters · filed 2019-11-01
2018-06-30-$27.52M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09
-$57.80M
10-Q · filed 2019-08-09
-$98.29M
derived: sum of 3 quarters · filed 2019-08-09
-$130.65M
derived: sum of 4 quarters · filed 2019-08-09
2018-03-31-$30.28M
10-Q · filed 2019-05-09
-$70.77M
derived: sum of 2 quarters · filed 2019-05-09
-$103.12M
derived: sum of 3 quarters · filed 2019-05-09
2017-12-31-$40.48M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07
-$72.84M
derived: sum of 2 quarters · filed 2019-03-07
-$127.79M
10-K · filed 2019-03-07
2017-09-30-$32.36M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09
-$87.31M
10-Q · filed 2018-11-09
2017-06-30-$54.95M
10-Q · filed 2018-08-07
2014-06-30-$8.37M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
-$17.12M
10-Q · filed 2014-08-07
2014-03-31-$8.74M
10-Q · filed 2014-05-07
2013-12-31-$33.72M
10-K · filed 2014-03-07
2013-06-30-$15.04M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
-$27.66M
10-Q · filed 2014-08-07
-$39.12M
derived: sum of 3 quarters · filed 2014-08-07
-$49.16M
derived: sum of 4 quarters · filed 2014-08-07
-$476.54M
10-Q · filed 2013-08-07
2013-03-31-$12.62M
10-Q · filed 2014-05-07
-$24.07M
derived: sum of 2 quarters · filed 2014-05-07
-$34.12M
derived: sum of 3 quarters · filed 2014-05-07
-$43.06M
derived: sum of 4 quarters · filed 2014-05-07
-$461.50M
10-Q · filed 2013-05-08
2012-12-31-$11.46M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07
-$21.50M
derived: sum of 2 quarters · filed 2014-03-07
-$30.44M
derived: sum of 3 quarters · filed 2014-03-07
-$40.37M
10-K · filed 2014-03-07
-$448.88M
10-K · filed 2013-03-15
2012-09-30-$10.04M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07
-$18.99M
derived: sum of 2 quarters · filed 2013-08-07
-$28.91M
10-Q · filed 2012-11-07
-$40.79M
derived: sum of 4 quarters · filed 2014-03-07
-$437.42M
10-Q · filed 2012-11-07
2012-06-30-$8.94M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07
-$18.87M
10-Q · filed 2013-08-07
-$30.75M
derived: sum of 3 quarters · filed 2014-03-07
-$41.39M
derived: sum of 4 quarters · filed 2014-03-07
-$427.38M
10-Q · filed 2012-08-06
2012-03-31-$9.93M
10-Q · filed 2013-05-08
-$21.81M
derived: sum of 2 quarters · filed 2014-03-07
-$32.44M
derived: sum of 3 quarters · filed 2014-03-07
-$46.08M
derived: sum of 4 quarters · filed 2014-03-07
-$418.44M
10-Q · filed 2012-05-04
2011-12-31-$11.88M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07
-$22.52M
derived: sum of 2 quarters · filed 2014-03-07
-$36.15M
derived: sum of 3 quarters · filed 2014-03-07
-$47.86M
10-K · filed 2014-03-07
-$408.51M
10-K · filed 2012-03-13
2011-09-30-$10.64M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07
-$24.27M
derived: sum of 2 quarters · filed 2012-11-07
-$35.98M
10-Q · filed 2012-11-07
-$47.59M
derived: sum of 4 quarters · filed 2013-03-15
-$396.63M
10-Q · filed 2011-11-04
2011-06-30-$13.63M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-06
-$25.34M
10-Q · filed 2012-08-06
-$36.96M
derived: sum of 3 quarters · filed 2013-03-15
-$49.30M
derived: sum of 4 quarters · filed 2013-03-15
-$385.99M
10-Q · filed 2011-08-04
2011-03-31-$11.71M
10-Q · filed 2012-05-04
-$23.32M
derived: sum of 2 quarters · filed 2013-03-15
-$35.67M
derived: sum of 3 quarters · filed 2013-03-15
2010-12-31-$11.61M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15
-$23.95M
derived: sum of 2 quarters · filed 2013-03-15
-$49.29M
10-K · filed 2013-03-15
2010-09-30-$12.34M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04
-$37.67M
10-Q · filed 2011-11-04
2010-06-30-$25.33M
10-Q · filed 2011-08-04
2009-12-31$24.54M
10-K · filed 2012-03-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
Alkermes plc. (ALKS)$6.844B132.74